AOD-9604 vs BPC-157
Side-by-side comparison of key properties, dosing, and research.
- Summary
- AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
- BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in the stomach. It is one of the most extensively researched healing peptides, known for accelerating tissue repair, reducing inflammation, and protecting the gastrointestinal tract.
- Half-Life
- 30-45 minutes injectable; longer with nasal spray formulation
- 4–6 hours
- Admin Route
- SubQ, Intranasal, Oral
- SubQ, IM, Oral
- Research
- —
- —
- Typical Dose
- 300-600 mcg
- 200–500 mcg
- Frequency
- Once daily
- Once daily
- Key Benefits
- Selective fat loss without anabolic side effects
- No effect on blood glucose or insulin resistance
- Improved bioavailability over Fragment 176-191
- GRAS (Generally Recognized As Safe) status in Australia
- Potential cartilage repair and anti-inflammatory properties
- Does not suppress natural GH production
- Accelerates wound healing and tissue repair
- Reduces inflammation throughout the body
- Protects and heals the gastrointestinal tract
- Supports tendon and ligament healing
- Promotes bone and joint health
- May protect organs from toxins and injury
- Supports gut-brain axis function
- Counteracts NSAID-induced gut damage
- Side Effects
- Localized injection site reactions
- Headache (rare)
- Hypoglycemia risk in combination with insulin (very rare)
- Injection site discomfort
- Nausea (rare)
- Headache (rare)
- Dizziness (rare)
- Stacks With
- —
- —